Erythrocin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Erythrocin

Property Description
Active ingredient Erythromycin
Forms Oral tablets, ophthalmic ointment, topical solution, injectable solution
Pharmacological class Macrolide Antibiotic
General purpose To counteract bacterial infections
Origin Natural (derived from Saccharopolyspora erythraea)

What Type of Medicine is Erythrocin (Erythromycin)?

Erythrocin is a prescription drug that contains the active ingredient Erythromycin, which is classified as an antibiotic belonging specifically to the macrolide pharmacological class. The general purpose of this medication is to act as an antimicrobial agent to help the body address and resolve bacterial infections. Erythromycin is recognized for its role as a macrolide antimicrobial.

Erythromycin is used to treat infections in diverse patient groups. It is frequently chosen by physicians for patients who require antibiotic intervention but have documented sensitivities or an allergy to penicillin, offering an established alternative. Its classification as a macrolide is determined by its unique chemical structure, which dictates how it engages with bacterial cells to contain the spread of infection.


Composition and Origin: The Natural Macrolide

The primary component of Erythrocin is Erythromycin, which is an active substance derived from a process involving the natural soil bacterium Saccharopolyspora erythraea, confirming its origin. This specific derivation classifies it as a polyketide antibiotic. The core chemical structure is characterized by a large lactone ring, which is the distinguishing feature of macrolides and is essential for its therapeutic function. Macrolide antibiotics interfere with bacterial protein synthesis to prevent growth and replication. This indicates that the medication functions to contain the infection by limiting the bacteria's ability to proliferate.

When formulated into pharmaceutical products, the active substance may be prepared as Erythromycin base or converted into various salts or esters—such as stearate or ethylsuccinate—to enhance its stability and absorption within the body. Erythrocin is consistently formulated as a single-ingredient product, ensuring that its therapeutic effect is solely attributable to the action of Erythromycin against infectious bacteria.


Forms and Preparations of the Single-Ingredient Product

Erythrocin is manufactured in several distinct dosage forms tailored for diverse patient needs and infection sites, including various types of oral tablets (such as specialized delayed-release formulations), topical solution, ophthalmic ointment, and sterile injectable solution.

This range of preparations ensures that the active ingredient can be delivered through multiple routes of administration, including oral ingestion, direct topical application to the skin or eye, or intravenous administration for systemic infections. The variation in form reflects the medical requirement to deliver the active substance most effectively to the specific site of the bacterial infection.

Regulatory References

  1. Macrolide Antibiotics Mechanism of Action (NIH)

What side effects are possible with Erythrocin?

Possible side effects and safety information

Regulatory documentation formally classifies possible adverse reactions to Erythrocin (Erythromycin) across various System-Organ Classes. The most Common adverse reactions typically involve the Gastrointestinal system, often including nausea, vomiting, abdominal pain, and diarrhea. These effects reflect the medication's official safety profile as established by government health authorities.


Serious Adverse Reactions

The official safety profile highlights the potential for rare but clinically significant adverse reactions. These include serious Cardiac disorders such as the prolongation of the QT interval and the risk of ventricular arrhythmias, including Torsade de Pointes. Reports of serious Hepatobiliary disorders, specifically hepatitis and cholestatic jaundice, are also documented. Additionally, rare, severe skin reactions, known as Severe Cutaneous Adverse Reactions (SCARs), and Pseudomembranous Colitis are listed in regulatory sources.


Population-Specific Safety Considerations

Official labeling contains specific safety statements for certain patient groups. Use in neonates (infants under one month of age) is associated with the documented risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). Caution is required when administering this medication to patients with pre-existing hepatic impairment due to the drug’s elimination route. Furthermore, older adults may have an increased risk of certain cardiac side effects, such as QT prolongation.

Deafness or hearing loss, an officially documented effect, is often associated with high doses or in patients with renal or hepatic impairment and is frequently noted as being reversible upon discontinuation. The use of Erythrocin is contraindicated in individuals with known hypersensitivity to macrolide antibiotics or a history of certain pre-existing cardiac arrhythmias.

Overdose and Emergency Response

Overdosage with Erythrocin is formally documented in regulatory labeling and requires immediate attention due to the risk of severe outcomes. Documented overdose presentations primarily involve acute gastrointestinal distress, encompassing nausea, vomiting, abdominal pain, and diarrhea. In addition, high exposures are officially associated with the risk of transient hearing loss, or ototoxicity, which is typically reversible.

The most critical documented risk is the potential for cardiotoxicity. Overdosage is linked to the prolongation of the QT interval, which can lead to life-threatening ventricular arrhythmias, such as Torsades de pointes, and has been tragically linked to cardiac arrest and fatalities in reported cases. Furthermore, regulatory information notes that patients with pre-existing renal or hepatic impairment may have a heightened susceptibility to adverse effects like reversible hearing loss due to elevated serum concentrations.

In the event of suspected overdosage, regulatory documents mandate that individuals must seek immediate medical attention by contacting emergency services or a Poison Control center. Treatment is defined as strictly symptomatic and supportive care, as there is no specific antidote known for Erythromycin overdose. Management may involve appropriate monitoring and supportive procedures to address any severe cardiac or neurological manifestations.

Therapeutic Uses of Erythrocin

What Erythrocin Treats: Main Uses and Benefits

This medication is generally used to provide supportive treatment for bacterial infections across several key symptomatic areas. Its use is applied across domains where additional symptomatic support is needed.

Erythrocin is commonly used for respiratory illnesses, including certain types of pneumonia, Whooping Cough (Pertussis), and Acute Otitis Media (ear infection); for localized issues like Acne vulgaris and Rosacea; and for specific sexually transmitted infections such as Chlamydia and Syphilis. The treatment helps relieve symptoms related to physical discomfort like severe coughing, fever, and pain. It generally assists with maintaining comfort and stability during the symptomatic period.

The medication is considered relevant in clinical settings where its use is an established alternative for patients where supportive antibacterial management is appropriate and who have a documented allergy or hypersensitivity to penicillin drugs. In these contexts, it helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Support for Acute Symptom Clusters Erythrocin is commonly applied in scenarios where symptoms may intensify temporarily, providing support that helps ease the overall symptom burden and assists with maintaining functional stability.

Eligibility and Restrictions for Use

Population Eligibility for Erythrocin (Erythromycin)

Official regulatory documents define specific populations who are restricted or prohibited from using Erythrocin. Use is contraindicated for patients with a known hypersensitivity to erythromycin or other macrolide antibiotics.

Absolute non-eligibility is also established for individuals with a pre-existing history of QT prolongation or other ventricular cardiac arrhythmias. Furthermore, the medicine must not be used concurrently with certain medications, including Lovastatin, Simvastatin, Terfenadine, Astemizole, or Pimozide, due to regulatory-mandated restrictions.

Conditional Use and Special Populations

Population Group Eligibility Restriction Status
Hepatic Impairment Use requires caution and monitoring, as the drug is primarily eliminated by the liver.
Infants Use requires special consideration due to the documented risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Older Adults May be more susceptible to cardiac effects, requiring caution.
Pregnancy Use is limited to scenarios where it is clearly needed.

Eligibility is also restricted for patients with uncorrected electrolyte imbalances, specifically hypokalemia or hypomagnesemia, due to cardiac risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Erythromycin, the active ingredient in Erythrocin, is documented in official regulatory labeling to participate in clinically significant drug interactions. These interactions are primarily classified as pharmacokinetic due to the medicine's role as an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) transporter.

Official Regulatory Restrictions

Co-administration with Erythromycin can lead to increased plasma concentrations and reduced clearance of numerous co-administered drugs. This elevated exposure can result in toxicity and necessitates specific regulatory restrictions:

  • Contraindicated Combinations: Co-administration is formally prohibited with substances such as Pimozide, Ergotamine, Dihydroergotamine, and CYP3A4-metabolized statins like Lovastatin and Simvastatin. These prohibitions are due to risks including cardiac events, acute ergot toxicity, and rhabdomyolysis.
  • Exposure-Modifying Drugs: The levels of many drugs are officially documented to increase, including Digoxin, Cyclosporine, Theophylline, Carbamazepine, and Sildenafil, requiring careful consideration.

Other Interaction Contexts

  • Pharmacodynamic Risk: An additive risk of QT interval prolongation exists when Erythromycin is combined with other agents known to affect the QT interval, such as certain antiarrhythmics.
  • Timing Constraints: The official labeling requires separation in administration timing for certain products, such as Aluminum/Magnesium-containing antacids.
  • Population Notes: The interaction risk with Colchicine is explicitly noted as being heightened in patients with renal or hepatic impairment.

Mechanism of Action

How Erythrocin Works: Mechanism of Action

Erythrocin (Erythromycin) exerts its action through two primary, distinct mechanistic domains. The core antimicrobial effect results from its action as an inhibitor that selectively binds to the 50S ribosomal subunit of susceptible bacteria. This interaction occurs near the polypeptide exit tunnel, physically blocking the translocation step of protein synthesis. Halting the elongation of necessary peptide chains leads to the physiological outcome of bacteriostasis (inhibition of bacterial growth).

Separately, the drug engages a human physiological pathway by functioning as a motilin receptor agonist on gastrointestinal smooth muscle cells. This action stimulates the migrating motor complex (MMC), causing an increase in the force and frequency of intestinal and gastric contractions. The consequence is a predictable pro-kinetic increase in gastric emptying and intestinal transit.

Erythrocin also acts as an inhibitor of the key hepatic enzyme Cytochrome P450 3A4 ( CYP3 A4). By blocking this metabolic pathway, the drug reduces the clearance of co-administered medications that rely on CYP3 A4 for breakdown, resulting in an increased systemic concentration of those substances.

Dosage and Administration Information

Administration Routes and Scheduling

Erythrocin is administered via multiple routes, including oral (using tablets, delayed-release forms, and suspensions), intravenous (IV) infusion, and localized topical or ophthalmic applications. The standard adult oral dosing generally ranges from 1 gram up to a maximum of 4 grams per day, with the total amount divided into equally spaced doses, such as 250 mg every six hours. Twice-daily dosing is typically not applied when the total daily dose exceeds 1 g.

For certain oral salt forms, such as Erythromycin Base tablets, administration should occur in a fasting state, ideally 30 minutes to 2 hours before meals, to optimize systemic absorption. Conversely, delayed-release and ethylsuccinate formulations may be used without regard to food.

Population Dosing and Procedural Conditions

Pediatric use involves a dose calculated by body weight, commonly 30 to 50 mg/kg per day in divided doses, with a maximum limit of 4 g daily. The length of the treatment course for specific conditions, such as streptococcal infections, requires a minimum commitment of 10 days.

Intravenous administration is reserved for severe infections and requires the drug to be administered as a slow intermittent infusion, lasting 20 to 60 minutes, and must not be delivered as a rapid bolus. IV use is switched to the oral form as soon as the patient's condition permits continued therapy. If a dose is missed, taking a double dose is avoided; the recommendation is to return to the regular schedule if the next dose time is near.

Recent Clinical Evidence

Research evidence / Overview of studies for Erythrocin

Evidence for Use in Treating Common Bacterial Infections

Research on Erythrocin's application for typical bacterial infections, such as those affecting the respiratory tract and skin, includes short-term Randomized Controlled Trials (RCTs) and formal Clinical Efficacy Studies. These efforts focused on observed populations, including adults with mild to moderate infections and specific pediatric groups. Studies monitored measured endpoints, which included the observation of changes in the signs and symptoms of infection, along with outcomes related to Pathogen status.

Studies conducted during periods of increased symptom activity reported measurements of both clinical outcomes and microbiological status following the therapeutic course, typically lasting from 7 to 21 days. Evidence in this area describes patterns observed in the populations studied. The potential for emerging resistance among specific bacterial strains was observed in some studies, a finding relevant to ongoing research.

Evidence for Use in Specific Systemic Conditions and Special Populations

Erythrocin was studied for its use as an antimicrobial alternative in conditions like certain sexually transmitted infections (STIs). Research has explored its role in patient groups, including those with a documented hypersensitivity to penicillin drugs. Findings describe group patterns related to its status as a recognized alternative agent.

For conditions like Chronic Obstructive Pulmonary Disease (COPD), research explored long-term studies lasting over extended periods (up to 12 months), examining the Frequency and Duration of acute symptom clusters. Research on this long-term use is limited to specific patient groups, and long-term effects are not fully established beyond the observed study duration.

Key Areas of Uncertainty and Research Gaps

Research has explored the action of Erythrocin on gastric motility in short-term studies, and findings describe patterns related to measured outcomes in systemic or functional imbalance. The available evidence includes data where evidence quality varies across studies. Comparative evidence is lacking for certain newer first-line treatments, and data for certain severe presentations remain insufficient. Study results reflect the specific conditions under which they were conducted. Research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Long-term macrolide treatment in patients with chronic obstructive pulmonary disease: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Erythrocin (FAQ)


Q: Is it common to feel tired while taking Erythrocin?

Official safety documents list specific adverse reactions associated with Erythrocin. While general fatigue or tiredness may occur, it is not consistently listed among the most common adverse effects, which are primarily related to the gastrointestinal system.


Q: Can Erythrocin cause stomach upset or nausea?

Regulatory sources indicate that gastrointestinal problems are the most common adverse reactions reported. This commonly includes nausea, vomiting, diarrhea, and abdominal pain.


Q: What is the difference between Erythrocin and penicillin?

Erythrocin, which contains the active ingredient erythromycin, is classified as a macrolide antibiotic, whereas penicillin is in a different pharmacological class. Due to this difference, official information indicates Erythrocin is often used as an established alternative for patients who have a documented allergy or hypersensitivity to penicillin.


Q: Are there any major food groups to avoid while on Erythrocin?

Regulatory documents primarily mention grapefruit and grapefruit juice interaction. No other major food groups are consistently listed for strict avoidance, but some forms of the medicine require administration in a fasting state for optimal absorption.


Q: Can older adults typically use Erythrocin?

Official labeling addresses the use of Erythrocin in older adults, but notes that caution is required. This is because official documents indicate that this population may have an increased susceptibility to certain cardiac side effects, such as changes in the heart's electrical activity.


Q: Is Erythrocin considered safe during pregnancy or breastfeeding, according to official sources?

For pregnancy, official documents limit use to scenarios where the medicine is clearly needed. For breastfeeding, the active ingredient does transfer into breast milk. Official information describes that monitoring the infant for effects, particularly gastrointestinal issues, is advised.


Q: What research themes are commonly studied regarding Erythrocin?

Research themes described in official overviews focus on its use in common bacterial infections (e.g., respiratory and skin), its role as an alternative in specific sexually transmitted infections, and its effect on gastric motility (how the stomach and intestines move food).


Q: Can I take Erythrocin with pain relievers like ibuprofen?

Official drug labeling does not typically list common pain relievers like ibuprofen as a major interacting drug. However, the potential for interactions with all non-prescription or over-the-counter medicines means that any co-administration requires consideration of patient-specific risks.


Q: Does Erythrocin affect birth control pills?

Official documents suggest Erythrocin may reduce the effectiveness of certain hormonal contraceptives that contain ethinyl estradiol. If this interaction is relevant, additional contraceptive methods may need to be considered.


Q: Does Erythrocin interact with alcohol?

Regulatory-aligned consumer information often mentions that alcohol consumption may need to be avoided or limited during the course of treatment. This is primarily because alcohol may increase the risk of gastrointestinal side effects and potentially reduce the effectiveness of the antibiotic treatment.


Q: Can Erythrocin cause dizziness or headaches?

While not listed among the most common adverse reactions, regulatory-aligned consumer information indicates that side effects affecting the central nervous system, such as headaches and dizziness, are documented as possible, less common effects.


Q: What happens if I miss a dose of Erythrocin?

Official instructions state that if a dose is missed, a double dose must not be taken to compensate for the missed one. Instead, a return to the regular schedule is recommended if the next dose time is near.


Q: Are there specific heart-related concerns linked to Erythrocin mentioned in official documents?

Yes, official documents highlight potential serious cardiac concerns. These include the prolongation of the QT interval and a rare risk of ventricular arrhythmias, such as Torsade de Pointes.


Q: Can Erythrocin be used for ear infections?

While official uses broadly cover bacterial infections of the respiratory tract, specific health agencies confirm that Erythrocin is often used in children for various infections, which includes certain types of ear infections.


Q: Is Erythrocin safe to use with antacids?

Official labeling addresses the co-administration of Erythrocin with antacids. It states that the use of certain antacids containing aluminum or magnesium requires separation in administration timing to prevent the antacid from affecting how the medicine is absorbed.


Q: Are there specific warnings about Erythrocin use for people with kidney problems?

Yes. Warnings specify that deafness or hearing loss is often associated with high doses or in patients with renal (kidney) impairment. Official documents also note that the interaction risk with the medicine colchicine is heightened in patients with kidney problems.


Q: Why might a doctor prescribe Erythrocin instead of amoxicillin?

Official information states that Erythrocin is frequently chosen as an established alternative for patients who require antibiotic treatment but have documented sensitivities or an allergy to penicillin and related drugs like amoxicillin.


Q: Is there a generic version of Erythrocin available?

Official sources, such as the FDA, list generic versions of the active ingredient, erythromycin, as approved for manufacturing in various formulations.


Q: Is Erythrocin widely used in children, based on official information?

Official documents define weight-based pediatric dosing, and certain health agencies specify that it is often used in children for various infections. However, official information cautions that special consideration is required for use in infants due to a specific safety risk.


Q: What does official data say about Erythrocin's use in patients with liver issues?

Official documentation states that caution is required when administering to patients with pre-existing hepatic impairment (liver issues) due to the drug’s primary elimination route. Reports of liver dysfunction, including hepatitis, are documented.


Q: Does Erythrocin treat sexually transmitted infections?

The active ingredient erythromycin is an FDA-approved treatment for a range of bacterial infections. This includes certain types of sexually transmitted infections, and research has explored its role as an alternative agent for these conditions.


Q: Are there any long-term effects of using Erythrocin that are widely discussed?

Research has explored long-term use in specific patient groups, such as those with COPD, over extended periods. However, the core evidence section states that long-term effects are not fully established beyond the observed duration of these studies.


Q: Is Erythrocin available over the counter in some countries?

In many major countries, including the United States, the United Kingdom, and Australia, Erythrocin is formally classified as a prescription-only medicine. While regulatory statuses can vary internationally, it generally requires a prescription.


Q: Why is Erythrocin sometimes referred to as an older antibiotic?

Erythrocin's active ingredient, erythromycin, was first discovered and isolated in the 1950s. This early date of discovery classifies it as an established, older drug when compared to newer macrolides and other classes of antibiotics developed more recently.

How should Erythrocin be stored and disposed of?

How to Store and Dispose of Erythrocin (Erythromycin)

Official regulatory guidelines define specific storage and disposal requirements for Erythrocin to maintain its stability.


Storage Conditions

Dosage Form Required Storage Condition
Oral Tablets Store at controlled room temperature (20 C to 25 C), protected from moisture and excessive heat in the tightly closed, original container.
Reconstituted Suspension Store in the refrigerator (2 C to 8 C). Do not freeze and discard after 10 days.

All forms must be stored out of the sight and reach of children.


️ Disposal Instructions

Unused or expired Erythrocin should be disposed of by following a local drug take-back program. It must not be disposed of by pouring it down a drain or flushing it unless specifically authorized by official instructions. These guidelines are set to ensure safety and prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Erythrocin found in:

A-Z Index: